Product development of Cirlo GmbH is based on pharmacological and clinical expertise in translational medicine in order to develop innovative stent-like scaffolds in a patient-friendly manner. We are expanding standard therapies in oncology and regenerative medicine. The aim is a personalized treatment based on patented scaffold platforms. Our development focuses on the well-being of the patient.


Pancreatic cancer is the fourth most common cause of cancer death in Germany (Center for Cancer Registry Data, 2021). The 5-year survival rates are so far only about 9% (Center for Cancer Registry Data, 2021). Since pancreatic cancer rarely causes symptoms in the early stages, it is usually diagnosed at an advanced stage. Standard therapy includes tumor resection, although this is just possible in less than 25% of cases (American Cancer Society, 2021). Furthermore, combination chemotherapies such as FOLFIRINOX, which are associated with significant side effects (N Engl J Med 2018). In addition, pancreatic cancer metastasizes early to the liver. Our innovative OncoStent scaffold offers various therapeutic options for patients in need.

Lead Project

OncoStent scaffold

The innovative OncoStent scaffolds enable new combination therapies that are characterized by higher local efficacy without dose-limiting side effects. Our focus lies on hematogenous metastasis to the liver. The uniqueness of the OncoStent scaffolds allows for the protection of the liver as an important organ, while fighting the growth of the cancer.

Our technology platform enables short and long term therapies and the implantation of our device is minimally invasive and can be handled by an interventional radiologist.